Dr. Reddy's Laboratories Limited (NYSE: RDY) Stock Competitors & Peer Comparison
See RDY's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RDY and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RDY | $12.22 | +0.91% | 10.2B | 20.01 | $0.61 | +0.68% |
| TAK | $17.45 | +2.53% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $10.03 | +0.00% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.36 | +1.58% | 41.2B | 12.06 | $2.93 | N/A |
| VTRS | $16.43 | +0.86% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.12 | -8.60% | 11B | 20.86 | $1.06 | N/A |
| LNTH | $100.95 | -0.12% | 6.6B | 16.97 | $5.95 | N/A |
| AMRX | $18.14 | +0.39% | 5.8B | 20.16 | $0.90 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
RDY vs TAK Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TAK trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TAK's P/E ratio is 12.55. In terms of profitability, RDY's ROE is +0.09%, compared to TAK's ROE of +0.02%. Regarding short-term risk, RDY is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for RDY.Check TAK's competition here
Haleon plc (NYSE: HLN)
RDY vs HLN Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas HLN's P/E ratio is 25.11. In terms of profitability, RDY's ROE is +0.09%, compared to HLN's ROE of +0.17%. Regarding short-term risk, RDY is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
RDY vs TEVA Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TEVA trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TEVA's P/E ratio is 12.06. In terms of profitability, RDY's ROE is +0.09%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, RDY is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
RDY vs VTRS Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while VTRS trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas VTRS's P/E ratio is 6.52. In terms of profitability, RDY's ROE is +0.09%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, RDY is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
RDY vs ITCI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ITCI's P/E ratio is -180.64. In terms of profitability, RDY's ROE is +0.09%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, RDY is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
RDY vs CTLT Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CTLT's P/E ratio is -27.84. In terms of profitability, RDY's ROE is +0.09%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, RDY is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for RDY.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
RDY vs ELAN Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ELAN trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ELAN's P/E ratio is 20.86. In terms of profitability, RDY's ROE is +0.09%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, RDY is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ELAN's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
RDY vs LNTH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while LNTH trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas LNTH's P/E ratio is 16.97. In terms of profitability, RDY's ROE is +0.09%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, RDY is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
RDY vs AMRX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while AMRX trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas AMRX's P/E ratio is 20.16. In terms of profitability, RDY's ROE is +0.09%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, RDY is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
RDY vs INDV Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while INDV trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas INDV's P/E ratio is 10.64. In terms of profitability, RDY's ROE is +0.09%, compared to INDV's ROE of -2.16%. Regarding short-term risk, RDY is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for RDY.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
RDY vs SUPN Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SUPN trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SUPN's P/E ratio is 15.57. In terms of profitability, RDY's ROE is +0.09%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, RDY is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
RDY vs RGC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas RGC's P/E ratio is -380.99. In terms of profitability, RDY's ROE is +0.09%, compared to RGC's ROE of -2.32%. Regarding short-term risk, RDY is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
RDY vs BHC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while BHC trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas BHC's P/E ratio is 1.59. In terms of profitability, RDY's ROE is +0.09%, compared to BHC's ROE of +0.89%. Regarding short-term risk, RDY is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
RDY vs DCPH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas DCPH's P/E ratio is -11.58. In terms of profitability, RDY's ROE is +0.09%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, RDY is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
RDY vs HCM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while HCM trades at $12.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas HCM's P/E ratio is 4.69. In terms of profitability, RDY's ROE is +0.09%, compared to HCM's ROE of +0.01%. Regarding short-term risk, RDY is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
RDY vs AVDL Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, RDY's ROE is +0.09%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, RDY is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for RDY.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
RDY vs EMBCV Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas EMBCV's P/E ratio is N/A. In terms of profitability, RDY's ROE is +0.09%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, RDY is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
RDY vs DVAX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas DVAX's P/E ratio is -41.89. In terms of profitability, RDY's ROE is +0.09%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, RDY is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
RDY vs ANIP Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ANIP's P/E ratio is 9.52. In terms of profitability, RDY's ROE is +0.09%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, RDY is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
RDY vs PRGO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PRGO trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PRGO's P/E ratio is 5.13. In terms of profitability, RDY's ROE is +0.09%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, RDY is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
RDY vs TARO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TARO's P/E ratio is 30.05. In terms of profitability, RDY's ROE is +0.09%, compared to TARO's ROE of +0.03%. Regarding short-term risk, RDY is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for RDY.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
RDY vs HROW Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while HROW trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas HROW's P/E ratio is 449.33. In terms of profitability, RDY's ROE is +0.09%, compared to HROW's ROE of -0.34%. Regarding short-term risk, RDY is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
RDY vs PAHC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PAHC trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PAHC's P/E ratio is 11.70. In terms of profitability, RDY's ROE is +0.09%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, RDY is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
RDY vs ALVO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ALVO trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ALVO's P/E ratio is -11.21. In terms of profitability, RDY's ROE is +0.09%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, RDY is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
RDY vs ETON Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ETON trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ETON's P/E ratio is -637.14. In terms of profitability, RDY's ROE is +0.09%, compared to ETON's ROE of -0.06%. Regarding short-term risk, RDY is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
RDY vs CRON Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CRON trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CRON's P/E ratio is 29.44. In terms of profitability, RDY's ROE is +0.09%, compared to CRON's ROE of +0.06%. Regarding short-term risk, RDY is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
RDY vs PCRX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PCRX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PCRX's P/E ratio is 9.62. In terms of profitability, RDY's ROE is +0.09%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, RDY is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
RDY vs COLL Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas COLL's P/E ratio is 3.70. In terms of profitability, RDY's ROE is +0.09%, compared to COLL's ROE of +0.16%. Regarding short-term risk, RDY is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for RDY.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
RDY vs PETQ Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PETQ's P/E ratio is 83.73. In terms of profitability, RDY's ROE is +0.09%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, RDY is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for RDY.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
RDY vs AMPH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while AMPH trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas AMPH's P/E ratio is 7.09. In terms of profitability, RDY's ROE is +0.09%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, RDY is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
RDY vs IRWD Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas IRWD's P/E ratio is 5.54. In terms of profitability, RDY's ROE is +0.09%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, RDY is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for RDY.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
RDY vs EVO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while EVO trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas EVO's P/E ratio is -2.82. In terms of profitability, RDY's ROE is +0.09%, compared to EVO's ROE of -0.24%. Regarding short-term risk, RDY is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
RDY vs BDSI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas BDSI's P/E ratio is 6.82. In terms of profitability, RDY's ROE is +0.09%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, RDY is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for RDY.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
RDY vs TLRY Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TLRY's P/E ratio is -7.21. In terms of profitability, RDY's ROE is +0.09%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, RDY is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
RDY vs EOLS Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while EOLS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas EOLS's P/E ratio is -24.04. In terms of profitability, RDY's ROE is +0.09%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, RDY is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
RDY vs AQST Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas AQST's P/E ratio is -6.46. In terms of profitability, RDY's ROE is +0.09%, compared to AQST's ROE of +1.91%. Regarding short-term risk, RDY is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
RDY vs KMDA Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while KMDA trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas KMDA's P/E ratio is 20.77. In terms of profitability, RDY's ROE is +0.09%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, RDY is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
RDY vs CGC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CGC's P/E ratio is -0.58. In terms of profitability, RDY's ROE is +0.09%, compared to CGC's ROE of -0.31%. Regarding short-term risk, RDY is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
RDY vs TKNO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TKNO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TKNO's P/E ratio is -20.84. In terms of profitability, RDY's ROE is +0.09%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, RDY is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
RDY vs ALIM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ALIM's P/E ratio is 5.28. In terms of profitability, RDY's ROE is +0.09%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, RDY is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
RDY vs LNDC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas LNDC's P/E ratio is -4.04. In terms of profitability, RDY's ROE is +0.09%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, RDY is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
RDY vs EMBC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while EMBC trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas EMBC's P/E ratio is 1.70. In terms of profitability, RDY's ROE is +0.09%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, RDY is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
RDY vs ORGO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ORGO's P/E ratio is 62.00. In terms of profitability, RDY's ROE is +0.09%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, RDY is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
RDY vs TYHT Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TYHT's P/E ratio is -1.61. In terms of profitability, RDY's ROE is +0.09%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, RDY is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
RDY vs SIGA Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SIGA trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SIGA's P/E ratio is 11.30. In terms of profitability, RDY's ROE is +0.09%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, RDY is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
RDY vs LFCR Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while LFCR trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas LFCR's P/E ratio is -4.68. In terms of profitability, RDY's ROE is +0.09%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, RDY is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
RDY vs ACB Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ACB trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ACB's P/E ratio is -6.10. In terms of profitability, RDY's ROE is +0.09%, compared to ACB's ROE of -0.21%. Regarding short-term risk, RDY is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
RDY vs REPH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas REPH's P/E ratio is -8.04. In terms of profitability, RDY's ROE is +0.09%, compared to REPH's ROE of -0.22%. Regarding short-term risk, RDY is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
RDY vs DERM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas DERM's P/E ratio is -17.38. In terms of profitability, RDY's ROE is +0.09%, compared to DERM's ROE of -0.36%. Regarding short-term risk, RDY is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
RDY vs CRDL Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CRDL trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CRDL's P/E ratio is -5.05. In terms of profitability, RDY's ROE is +0.09%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, RDY is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
RDY vs THTX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas THTX's P/E ratio is -28.83. In terms of profitability, RDY's ROE is +0.09%, compared to THTX's ROE of +0.17%. Regarding short-term risk, RDY is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
RDY vs ASRT Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ASRT's P/E ratio is -7.10. In terms of profitability, RDY's ROE is +0.09%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, RDY is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
RDY vs OGI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while OGI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas OGI's P/E ratio is -3.81. In terms of profitability, RDY's ROE is +0.09%, compared to OGI's ROE of -0.07%. Regarding short-term risk, RDY is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
RDY vs CPIX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CPIX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CPIX's P/E ratio is -19.50. In terms of profitability, RDY's ROE is +0.09%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, RDY is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
RDY vs SCTL Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SCTL's P/E ratio is -7.86. In terms of profitability, RDY's ROE is +0.09%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, RDY is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for RDY.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
RDY vs PROC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PROC's P/E ratio is 1.53. In terms of profitability, RDY's ROE is +0.09%, compared to PROC's ROE of -2.22%. Regarding short-term risk, RDY is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for RDY.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
RDY vs OPTN Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas OPTN's P/E ratio is -4.42. In terms of profitability, RDY's ROE is +0.09%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, RDY is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for RDY.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
RDY vs ZOM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ZOM's P/E ratio is -1.62. In terms of profitability, RDY's ROE is +0.09%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, RDY is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
RDY vs ZYBT Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ZYBT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, RDY's ROE is +0.09%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, RDY is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
RDY vs GRVI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas GRVI's P/E ratio is 26.05. In terms of profitability, RDY's ROE is +0.09%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, RDY is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
RDY vs ZYNE Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, RDY's ROE is +0.09%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, RDY is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
RDY vs SSIC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SSIC's P/E ratio is 11.93. In terms of profitability, RDY's ROE is +0.09%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, RDY is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
RDY vs VLNS Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas VLNS's P/E ratio is -1.03. In terms of profitability, RDY's ROE is +0.09%, compared to VLNS's ROE of N/A. Regarding short-term risk, RDY is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
RDY vs BGM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas BGM's P/E ratio is -1.04. In terms of profitability, RDY's ROE is +0.09%, compared to BGM's ROE of -0.07%. Regarding short-term risk, RDY is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
RDY vs DRRX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas DRRX's P/E ratio is -4.44. In terms of profitability, RDY's ROE is +0.09%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, RDY is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
RDY vs INCR Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas INCR's P/E ratio is -2.26. In terms of profitability, RDY's ROE is +0.09%, compared to INCR's ROE of -0.09%. Regarding short-term risk, RDY is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for RDY.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
RDY vs JUPW Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas JUPW's P/E ratio is -2.41. In terms of profitability, RDY's ROE is +0.09%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, RDY is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for RDY.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
RDY vs QLI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas QLI's P/E ratio is -4.92. In terms of profitability, RDY's ROE is +0.09%, compared to QLI's ROE of -0.16%. Regarding short-term risk, RDY is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for RDY.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
RDY vs HEXO Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas HEXO's P/E ratio is -0.26. In terms of profitability, RDY's ROE is +0.09%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, RDY is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for RDY.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
RDY vs TLPH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TLPH trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TLPH's P/E ratio is -4.61. In terms of profitability, RDY's ROE is +0.09%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, RDY is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
RDY vs RMTI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while RMTI trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas RMTI's P/E ratio is -6.89. In terms of profitability, RDY's ROE is +0.09%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, RDY is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
RDY vs AYTU Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas AYTU's P/E ratio is -1.23. In terms of profitability, RDY's ROE is +0.09%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, RDY is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
RDY vs TXMD Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas TXMD's P/E ratio is 105.45. In terms of profitability, RDY's ROE is +0.09%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, RDY is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for RDY.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
RDY vs CYTH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CYTH's P/E ratio is -0.80. In terms of profitability, RDY's ROE is +0.09%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, RDY is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for RDY.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
RDY vs EVOK Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas EVOK's P/E ratio is -7.97. In terms of profitability, RDY's ROE is +0.09%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, RDY is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for RDY.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
RDY vs BFRIW Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, RDY's ROE is +0.09%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, RDY is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for RDY.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
RDY vs OPTH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while OPTH trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas OPTH's P/E ratio is -18.56. In terms of profitability, RDY's ROE is +0.09%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, RDY is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
RDY vs ACRX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ACRX's P/E ratio is -0.31. In terms of profitability, RDY's ROE is +0.09%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, RDY is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
RDY vs COSM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas COSM's P/E ratio is -0.38. In terms of profitability, RDY's ROE is +0.09%, compared to COSM's ROE of -0.96%. Regarding short-term risk, RDY is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
RDY vs AGRX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas AGRX's P/E ratio is -0.89. In terms of profitability, RDY's ROE is +0.09%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, RDY is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
RDY vs NLTX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas NLTX's P/E ratio is -0.28. In terms of profitability, RDY's ROE is +0.09%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, RDY is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for RDY.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
RDY vs LCI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas LCI's P/E ratio is -0.04. In terms of profitability, RDY's ROE is +0.09%, compared to LCI's ROE of +1.66%. Regarding short-term risk, RDY is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
RDY vs ADMP Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ADMP's P/E ratio is -0.08. In terms of profitability, RDY's ROE is +0.09%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, RDY is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for RDY.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
RDY vs YCBD Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas YCBD's P/E ratio is -1.38. In terms of profitability, RDY's ROE is +0.09%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, RDY is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for RDY.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
RDY vs GELS Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas GELS's P/E ratio is -1.09. In terms of profitability, RDY's ROE is +0.09%, compared to GELS's ROE of -0.25%. Regarding short-term risk, RDY is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for RDY.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
RDY vs MNK Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas MNK's P/E ratio is -0.44. In terms of profitability, RDY's ROE is +0.09%, compared to MNK's ROE of -0.26%. Regarding short-term risk, RDY is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for RDY.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
RDY vs FLGC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas FLGC's P/E ratio is -0.19. In terms of profitability, RDY's ROE is +0.09%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, RDY is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
RDY vs CPHI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CPHI's P/E ratio is -1.76. In terms of profitability, RDY's ROE is +0.09%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, RDY is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
RDY vs UPC Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while UPC trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas UPC's P/E ratio is -0.69. In terms of profitability, RDY's ROE is +0.09%, compared to UPC's ROE of -0.03%. Regarding short-term risk, RDY is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for RDY.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
RDY vs SBFM Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SBFM's P/E ratio is -0.20. In terms of profitability, RDY's ROE is +0.09%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, RDY is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
RDY vs SHPH Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SHPH trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SHPH's P/E ratio is -0.20. In terms of profitability, RDY's ROE is +0.09%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, RDY is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
RDY vs PLXP Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PLXP's P/E ratio is -0.22. In terms of profitability, RDY's ROE is +0.09%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, RDY is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for RDY.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
RDY vs SNOA Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while SNOA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas SNOA's P/E ratio is -1.22. In terms of profitability, RDY's ROE is +0.09%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, RDY is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
RDY vs ATNX Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas ATNX's P/E ratio is -0.02. In terms of profitability, RDY's ROE is +0.09%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, RDY is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for RDY.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
RDY vs PROCW Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas PROCW's P/E ratio is N/A. In terms of profitability, RDY's ROE is +0.09%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, RDY is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for RDY.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
RDY vs RDHL Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas RDHL's P/E ratio is 0.12. In terms of profitability, RDY's ROE is +0.09%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, RDY is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for RDY.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
RDY vs YCBD-PA Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, RDY's ROE is +0.09%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, RDY is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for RDY.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
RDY vs CYTHW Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas CYTHW's P/E ratio is N/A. In terms of profitability, RDY's ROE is +0.09%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, RDY is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for RDY.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
RDY vs LSDI Comparison August 2026
Dr. Reddy's Laboratories Limited (NYSE: RDY) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RDY stands at 10.2B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, RDY is priced at $12.22 on the NYSE, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RDY currently has a P/E ratio of 20.01, whereas LSDI's P/E ratio is -0.07. In terms of profitability, RDY's ROE is +0.09%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, RDY is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for RDY.Check LSDI's competition here